RACHEL WHITTEN: Open Payments
NPI 1104424795 · PUEBLO, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,420 in 72 payments from 22 companies in 2025. Trend: 2023 $381 · 2024 $900 · 2025 $1,420
Food & beverage: $1,420
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $210 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $208 |
| GlaxoSmithKline, LLC. | 11 | $202 |
| ABBVIE INC. | 5 | $103 |
| Novo Nordisk Inc | 6 | $95 |
| Novartis Pharmaceuticals Corporation | 3 | $78 |
| Astellas Pharma US Inc | 4 | $73 |
| Amgen Inc. | 4 | $60 |
| Dexcom, Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
Products named: CAPLYTA, AREXVY, LEQVIO, FARXIGA, Veozah, Ozempic, UBRELVY, TRELEGY ELLIPTA.
Industry payments across CO — which companies pay providers there.
